Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Children With Type 1 Diabetes in a Diabetes Camp

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02189694
Recruitment Status : Completed
First Posted : July 14, 2014
Last Update Posted : September 3, 2014
Sponsor:
Collaborator:
Montreal Children's Hospital of the MUHC
Information provided by (Responsible Party):
Rémi Rabasa-Lhoret, Institut de Recherches Cliniques de Montreal

Brief Summary:

Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormone: insulin and glucagon.

The main objective of this project is to compare the efficacy of single-hormone closed-loop strategy, dual-hormone closed-loop strategy and pump therapy to regulate overnight glucose levels in children with type 1 diabetes in a diabetes camp.

The investigators hypothesized that dual-hormone closed-loop strategy reduces the time spent in hypoglycemia in children with type 1 diabetes (T1D) compared to single-hormone closed-loop strategy, which in turn is more effective than the conventional pump therapy to reduce time spent in hypoglycemia


Condition or disease Intervention/treatment Phase
Type 1 Diabetes Device: Single-hormone closed-loop strategy Device: Dual-hormone closed-loop strategy Device: Insulin pump therapy Phase 2

Detailed Description:

Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormone: insulin and glucagon.

The investigators aim to conduct a randomized three-way cross-over trial comparing single hormone closed-loop strategy, dual-hormone closed-loop strategy and the conventional pump therapy. The investigators aim to compare the three interventions for 3 consecutive nights in children with type 1 diabetes in a diabetes camp.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Randomized, Three-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Pump Therapy in Regulating Overnight Glucose Levels in Children With Type 1 Diabetes in a Diabetes Camp
Study Start Date : June 2014
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014


Arm Intervention/treatment
Active Comparator: Insulin pump therapy
Glucose levels will be controlled for 3 consecutive nights using insulin pump therapy. Subjects will carry on with their normal conventional insulin pump therapy and will be allowed to freely implement therapeutic adjustments..
Device: Insulin pump therapy
Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.

Active Comparator: Single-hormone closed-loop strategy
Glucose levels will be controlled by single-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by single-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pump's parameters will then be changed manually to implement the computer generated recommendations.
Device: Single-hormone closed-loop strategy
Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.

Active Comparator: Dual-hormone closed-loop strategy
Glucose levels will be controlled by dual-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by dual-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor readings will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses. Pumps' parameters will then be changed manually to implement the computer generated recommendations.
Device: Dual-hormone closed-loop strategy
Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.




Primary Outcome Measures :
  1. Percentage of time of glucose levels spent below 4.0 mmol/L. [ Time Frame: Up to 8 hours ]

Secondary Outcome Measures :
  1. Percentage of time of glucose levels spent between 4.0 and 8.0 mmol/L [ Time Frame: Up to 8 hours ]
  2. Percentage of time of glucose levels spent below 3.5 mmol/L [ Time Frame: Up to 8 hours ]
  3. Percentage of time of glucose levels spent below 3.3 mmol/L [ Time Frame: Up to 8 hours ]
  4. Percentage of time of glucose levels spent above 8 mmol/L [ Time Frame: Up to 8 hours ]
  5. Percentage of time of glucose levels spent above 10 mmol/L. [ Time Frame: Up to 8 hours ]
  6. Area under the curve of glucose levels below 4.0 mmol/L [ Time Frame: Up to 8 hours ]
  7. Area under the curve of glucose levels below 3.5 mmol/L [ Time Frame: Up to 8 hours ]
  8. Area under the curve of glucose levels below 3.3 mmol/L [ Time Frame: Up to 8 hours ]
  9. Area under the curve of glucose levels above 8.0 mmol/L [ Time Frame: Up to 8 hours ]
  10. Area under the curve of glucose levels above 10.0 mmol/L. [ Time Frame: Up to 8 hours ]
  11. Mean glucose levels. [ Time Frame: Up to 8 hours ]
  12. Standard deviation of glucose levels [ Time Frame: Up to 8 hours ]
    Measure of glucose variability.

  13. Total insulin delivery [ Time Frame: Up to 8 hours ]
  14. Hypoglycemic risk assessed by the total number of hypoglycemic event (> 15 minutes) below 3.1 mmol/L [ Time Frame: Up to 8 hours ]
  15. Hypoglycemic risk assessed by the number of patients experiencing at least one hypoglycemic event (> 15 minutes) below 3.1 mmol/L [ Time Frame: Up to 8 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females between the 8 and 17 years of old.
  • Clinical diagnosis of type 1 diabetes for at least one year. The subject will have been on insulin pump therapy for at least 3 months.
  • HbA1c ≤ 11.0%.

Exclusion Criteria:

  • Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator.
  • Severe hypoglycemic episode within two weeks of inclusion in the study. A severe hypoglycemic episode is defined as loss of conscience, seizure or a hospital emergency visit.
  • Current use of oral glucocorticoid medication (except low stable dose according to investigator judgement). Stable doses of inhaled steroids are acceptable.
  • Known or suspected allergy to the trial products.
  • Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
  • Failure to comply with team's recommendations (e.g. not willing to use trial pump, etc).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02189694


Locations
Layout table for location information
Canada, Quebec
Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada, H2W 1R7
Sponsors and Collaborators
Institut de Recherches Cliniques de Montreal
Montreal Children's Hospital of the MUHC
Investigators
Layout table for investigator information
Principal Investigator: Rémi Rabasa-Lhoret, MD, PhD Institut de recherches cliniques de Montréal
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Rémi Rabasa-Lhoret, Associate professor of Medicine, Institut de Recherches Cliniques de Montreal
ClinicalTrials.gov Identifier: NCT02189694    
Other Study ID Numbers: CLASS-08
First Posted: July 14, 2014    Key Record Dates
Last Update Posted: September 3, 2014
Last Verified: September 2014
Keywords provided by Rémi Rabasa-Lhoret, Institut de Recherches Cliniques de Montreal:
Type 1 diabetes
Hypoglycemia
Insulin
Glucagon
Closed-loop system
Artificial pancreas
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Hormones
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists